Form 4: Dexcom Executive Michael Brown Sells Shares Under 10b5-1 Plan
SEC Form 4
Michael Brown, EVP and Chief Legal Officer of Dexcom Inc., sold 652 shares of common stock at $119.24 per share on May 31, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 31, 2024, Michael Jon Brown, the EVP and Chief Legal Officer of Dexcom Inc. (DXCM), sold 652 shares of Dexcom's common stock.
- The sale was executed at a price of $119.24 per share.
- The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on December 15, 2022, and amended on August 29, 2023.
- Following the transaction, Brown directly owns 67,560 shares of Dexcom common stock, which includes 60,303 unvested restricted stock units.
- These restricted stock units vest over several years, with grants made on March 8, 2022, March 8, 2023, and March 8, 2024, vesting through March 8, 2026 and March 8, 2027.
Sentiment
Score: 5
Explanation: The document is neutral in sentiment as it reports a routine stock sale by an executive under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
Executive stock sales are a common occurrence, especially when conducted under pre-arranged trading plans like the 10b5-1 plan, which allows insiders to sell shares at predetermined times to avoid accusations of insider trading. These sales can be influenced by personal financial planning rather than company performance.
Comparison to Industry Standards
- Executive stock sales are a routine part of corporate governance, and the use of 10b5-1 plans is widespread among executives at publicly traded companies like Dexcom.
- Comparable companies such as Abbott Laboratories (ABT) and Medtronic (MDT) also see regular Form 4 filings related to executive stock transactions.
- The volume of shares sold by Michael Brown is relatively small compared to the total outstanding shares of Dexcom, suggesting it is unlikely to have a significant impact on the stock price.
Stakeholder Impact
- The sale of shares by an executive could have a minor psychological impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.
- The transaction is unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/15/2022 | Mr. Brown adopted a 10b5-1 Plan. |
| 08/29/2023 | Mr. Brown's 10b5-1 Plan was amended. |
| 03/08/2022 | Grant date of 24,080 unvested restricted stock units which shall vest through March 8, 2026. |
| 03/08/2023 | Grant date of 14,512 unvested restricted stock units which shall vest through March 8, 2026. |
| 03/08/2024 | Grant date of 21,711 unvested restricted stock units which shall vest through March 8, 2027. |
| 05/31/2024 | Date of the transaction: Michael Brown sold 652 shares of Dexcom common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.